Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $220.00 at Chardan Capital

Krystal Biotech (NASDAQ:KRYS) had its price target boosted by Chardan Capital from $216.00 to $220.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently issued reports on KRYS. HC Wainwright restated a “buy” rating and set a $240.00 price objective on shares of Krystal Biotech in a research note on Monday, September 15th. Weiss Ratings restated a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Bank of America upped their price objective on Krystal Biotech from $182.00 to $255.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Citigroup restated a “neutral” rating and set a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, Guggenheim set a $224.00 price objective on Krystal Biotech and gave the company a “buy” rating in a research note on Friday, October 17th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.14.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $203.26 on Tuesday. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $212.98. The business has a 50-day moving average of $171.52 and a 200-day moving average of $153.16. The company has a market capitalization of $5.88 billion, a price-to-earnings ratio of 30.47 and a beta of 0.65.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, topping the consensus estimate of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The business had revenue of $97.80 million for the quarter, compared to analysts’ expectations of $93.72 million. Research analysts expect that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Krystal Biotech

Hedge funds have recently modified their holdings of the stock. Brooklyn Investment Group boosted its position in shares of Krystal Biotech by 291.7% in the first quarter. Brooklyn Investment Group now owns 141 shares of the company’s stock worth $25,000 after buying an additional 105 shares during the period. Hantz Financial Services Inc. boosted its position in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after buying an additional 179 shares during the period. Twin Tree Management LP acquired a new stake in shares of Krystal Biotech in the first quarter worth $29,000. AdvisorNet Financial Inc acquired a new stake in shares of Krystal Biotech in the third quarter worth $30,000. Finally, Salomon & Ludwin LLC acquired a new stake in shares of Krystal Biotech in the third quarter worth $33,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).